The development of cell and gene therapies (CGTs) is rapidly increasing. CGTs have many of the same manufacturing needs as biopharmaceuticals, in fact, they both use single-use technologies (SUTs) for reduced costs, time savings and sterility. But for CGTs, many SUTs cannot be transferred from laboratory scale into commercial manufacturing for a variety of reasons. Read our white paper to learn about these challenges and how SUTs in biopharmaceutical manufacturing may offer part of the solution – particularly in the area of connection technologies.
- Bioprocessing and CGT processes are similar and different
- The process setting influences the type of connection technology used
- An aseptic connector produces a sterile connection in a non-sterile environment
Fill in the form to download the Cell & Gene Therapies: A Guide To Single-Use Connections – 10 Transferable Lessons From The Bioprocessing Industry to learn more.